Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 362

Results For "UST"

3781 News Found

Evexia Lifecare to manufacture API of Isometa
News | August 03, 2021

Evexia Lifecare to manufacture API of Isometa

Robust demand for the product across the Middle East, Africa and Latin America


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.


NPPA monitors and caps prices of essential drugs: Mandaviya
Policy | August 03, 2021

NPPA monitors and caps prices of essential drugs: Mandaviya

NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level


NPPA caps prices on five medical devices effective July 20th 2021
Policy | August 03, 2021

NPPA caps prices on five medical devices effective July 20th 2021

The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers


Healthium Medtech acquires SGK Lab’s AbGel gelatin business
Healthcare | August 03, 2021

Healthium Medtech acquires SGK Lab’s AbGel gelatin business

Complementary business models are the reason for the acquisition


Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22